Unicycive's Q2 2026 Filing: Second OLC CRL, $13.8M Cash Burn, and $61.4M Runway
UNCY sits 35% above its 52-week low of $3.71 on light trading volume (0.3× avg).
Summary
Unicycive's Q2 2026 filing reveals a second CRL for OLC and a $13.8M operating cash burn, offset by $34.0M in ATM proceeds. Cash and securities of $61.4M provide a 12-month runway.
Key Events · Earnings and Guidance · UNCY
-
Second CRL for OLC
On June 30, 2026, the FDA issued a second Complete Response Letter for oxylanthanum carbonate, once again citing third-party manufacturing deficiencies. No clinical or safety issues were raised.
-
Cash Burn and Runway
Operating cash outflow reached $13.8M in H1 2026. As of June 30, 2026, cash and marketable securities totaled $61.4M, which management believes funds operations for at least 12 months.
-
ATM Proceeds
During H1 2026, the company sold 5.3M shares under its ATM program at an average price of $6.64, raising $34.0M net of commissions.
-
Non-Cash Warrant Gain
A $3.2M non-cash gain from the decrease in warrant liability—to $13.7M from $16.9M—reduced the reported net loss to $14.5M for H1 2026.
Analysis · UNCY · Life Sciences
The Q2 2026 10-Q from Unicycive discloses a second Complete Response Letter for its lead drug OLC, received on June 30, 2026, again pointing to the same third-party manufacturing deficiencies. With no approved products and no revenue, the company burned $13.8 million in operating cash during the first half. That drain was partially offset by $34.0 million raised through ATM sales at an average price of $6.64 per share—well above today's $4.99. Cash and marketable securities stand at $61.4 million, which management says is enough to fund operations for at least 12 months. A decline in the warrant liability from $16.9 million to $13.7 million produced a non-cash gain of $3.2 million, trimming the reported net loss to $14.5 million. The second CRL intensifies the regulatory overhang and raises the stakes for the remaining cash runway.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UNCY was trading at $4.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.5M. The 52-week trading range was $3.71 to $8.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.